Skip to main content
SpringerLink
Log in

Teserpaturev/G47Δ: First Approval

  • AdisInsight Report
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Teserpaturev/G47Δ (Delytact®) is a third-generation (triple-mutated) recombinant oncolytic herpes simplex virus type 1 being developed by Daiichi Sankyo Co., Ltd. for the treatment of certain solid cancers. Teserpaturev/G47Δ has been approved for the treatment of malignant glioma in Japan and is currently in clinical development for the treatment of prostate cancer (phase II), malignant pleural mesothelioma (phase I) and recurrent olfactory neuroblastoma (phase I). This article summarizes the milestones in the development of teserpaturev/G47Δ leading to this first approval for the treatment of malignant glioma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 2016;107:1373–9.

    Article  CAS  Google Scholar 

  2. Taguchi S, Fukuhara H, Todo T. Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives. Jpn J Clin Oncol. 2019;49(3):201–9.

    Article  Google Scholar 

  3. Bommareddy PK, Shettigar M. Kaufman HL Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol. 2018;18:498–513.

    Article  CAS  Google Scholar 

  4. Fukuhara H, Takeshima Y, Todo T. Triple-mutated oncolytic herpes virus for treating both fast- and slow-growing tumors. Cancer Sci. 2021;112(8):3293–301.

    Article  CAS  Google Scholar 

  5. Zeng J, Li X, Sander M, et al. Oncolytic viro-immunotherapy: an emerging option in the treatment of gliomas. Front Immunol. 2021;12: 721830.

    Article  CAS  Google Scholar 

  6. Kaufman HL, Bommareddy PK. Two roads for oncolytic immunotherapy development. J Immunother Cancer. 2019;7:26.

    Article  Google Scholar 

  7. Mondal M, Guo J, He P, et al. Recent advances of oncolytic virus in cancer therapy. Hum Vaccines Immunother. 2020;16(10):2389–402.

    Article  CAS  Google Scholar 

  8. Ghouse JN, Martuza SM, Rabkin SD. In situ cancer vaccination and immunovirotherapy using oncolytic HSV. Viruses. 2021;13:1740.

    Article  Google Scholar 

  9. Mineta T, Rabkin SD, Yazaki T, et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995;1(9):938–43.

    Article  CAS  Google Scholar 

  10. Otani Y, Yoo JY, Shimizu T, et al. Implications of immune cells in oncolytic herpes simplex virotherapy for glioma. Brain Tumor Pathol. 2022;39(2):57–64.

    Article  Google Scholar 

  11. Todo T, Ito H, Ino Y, et al. Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial. Nat Med. 2022;28:1630-9.

    Article  PubMed  PubMed Central  Google Scholar 

  12. UMIN Clinical Trials Registry. Unique UMIN ID UMIN000015995. http://upload.umin.ac.jp. Accessed 29 July 2022.

  13. Daiichi Sankyo Co. Ltd. DELYTACT® oncolytic virus G47∆ approved in Japan for treatment of patients with malignant glioma [media release]. 11 June 2021. https://www.daiichisankyo.com.

  14. Daiichi-Sankyo Co. Ltd. DELYTACT: Japanese package insert. 2021.

  15. Daiichi Sankyo Co. Ltd. Daiichi Sankyo launches DELYTACT(R) oncolytic virus G47 delta in Japan [media release]. 1 Nov 2021. https://www.daiichisankyo.com.

  16. Daiichi Sankyo Co. Ltd. Oncolytic virus G47delta (DS-1647) designated as orphan drug under Orphan Drug/Medical Device designation system [media release]. http://www.daiichisankyo.com. Accessed 19 July 2021.

  17. Daiichi Sankyo Co. Ltd. Daiichi Sankyo submits application for oncolytic virus teserpaturev (G47Δ) for treatment of patients with malignant glioma in Japan [media release]. http://www.daiichisankyo.com. Accessed 19 July 2021.

  18. Daiichi Sankyo Co. Ltd. Reference data (consolidated financial results for Q3 FY2020). http://www.daiichisankyo.com. Accessed 29 July 2022.

  19. Todo T, Martuza RL, Rabkin SD, et al. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA. 2001;98:6396–401.

    Article  CAS  Google Scholar 

  20. Zhang W, Fulci G, Wakimoto H, et al. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. Neoplasia. 2013;15(6):591–9.

    Article  CAS  Google Scholar 

  21. Barnard Z, Wakimoto H, Zaupa C, et al. Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma. Neurosurgery. 2012;71(3):741–8.

    Article  Google Scholar 

  22. Hoffmann D, Wildner O. Comparison of herpes simplex virus- and conditionally replicative adenovirus-based vectors for glioblastoma treatment. Cancer Gene Ther. 2007;14(7):627–39.

    Article  CAS  Google Scholar 

  23. Wakimoto H, Kesari S, Farrell CJ, et al. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 2009;69(8):3472–81.

    Article  CAS  Google Scholar 

  24. Cheema TA, Wakimoto H, Fecci PE, et al. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Natl Acad Sci USA. 2013;110(29):12006–11.

    Article  CAS  Google Scholar 

  25. Cheema TA, Kanai R, Kim GW, et al. Enhanced antitumor efficacy of low-dose etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. Clin Cancer Res. 2011;17(23):7383–93.

    Article  CAS  Google Scholar 

  26. Ning J, Wakimoto H, Peters C, et al. Rad51 degradation: role in oncolytic virus-poly(ADP-ribose) polymerase inhibitor combination therapy in glioblastoma. J Natl Cancer Inst. 2017;109(3):1–13.

    Article  Google Scholar 

  27. Kanai R, Rabkin SD, Yip S, et al. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. J Natl Cancer Inst. 2012;104(1):42–55.

    Article  CAS  Google Scholar 

  28. Nigim F, Esaki S, Hood M, et al. A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus. Neuro Oncol. 2016;18(9):1278–87.

    Article  CAS  Google Scholar 

  29. Saha D, Wakimoto H, Peters CW, et al. Combinatorial effects of VEGFR kinase inhibitor axitinib and oncolytic virotherapy in mouse and human glioblastoma stem-like cell models. Clin Cancer Res. 2018;24(14):3409–22.

    Article  CAS  Google Scholar 

  30. Esaki S, Nigim F, Moon E, et al. Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models. Int J Cancer. 2017;141(11):2348–58.

    Article  CAS  Google Scholar 

  31. Farrell CJ, Zaupa C, Barnard Z, et al. Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells. Clin Cancer Res. 2008;14(23):7711–6.

    Article  CAS  Google Scholar 

  32. Sugawara K, Iwai M, Ito H, et al. Oncolytic herpes virus G47Δ works synergistically with CTLA-4 inhibition through dynamic intratumoral immune modulation. Mol Ther Oncol. 2021;22:129–42.

    Article  CAS  Google Scholar 

  33. Fan J, Jiang H, Cheng L, et al. Oncolytic herpes simplex virus and temozolomide synergistically inhibit breast cancer cell tumorigenesis in vitro and in vivo. Oncol Lett. 2021;21(2):99.

    Article  Google Scholar 

  34. Sugawara K, Iwai M, Yajima S, et al. Efficacy of a third-generation oncolytic herpes virus G47Δ in advanced stage models of human gastric cancer. Mol Ther Oncol. 2020;17:205–15.

    Article  CAS  Google Scholar 

  35. Fan J, Jiang H, Cheng L, et al. The oncolytic herpes simplex virus vector, G47Δ, effectively targets tamoxifen-resistant breast cancer cells. Oncol Rep. 2016;35(3):1741–9.

    Article  CAS  Google Scholar 

  36. Wang L, Ning J, Wakimoto H, et al. Oncolytic herpes simplex virus and PI3K inhibitor BKM120 synergize to promote killing of prostate cancer stem-like cells. Mol Ther Oncol. 2019;13:58–66.

    Article  Google Scholar 

  37. Yamada T, Tateishi R, Iwai M, et al. Neoadjuvant use of oncolytic herpes virus G47Δ enhances the antitumor efficacy of radiofrequency ablation. Mol Ther Oncol. 2020;18:535–45.

    Article  CAS  Google Scholar 

  38. Ito H, Ino Y, Todo T. Therapeutic efficacy of third generation oncolytic HSV-1 (G47delta) for glioma cells with stem cell property [abstract]. In: 19th annual meeting of the American Society of Gene and Cell Therapy, 2016.

  39. Saha D, Martuza RL, Rabkin SD. Glioblastoma eradication by combination oncolytic immunovirotherapy and immune checkpoint blockade [abstract]. Mol Ther. 2017;25(5 Suppl 1):361.

    Google Scholar 

  40. Uchihashi T, Nakahara H, Fukuhara H, et al. Oncolytic herpes virus G47Δ injected into tongue cancer swiftly traffics in lymphatics and suppresses metastasis. Mol Ther Oncol. 2021;22:388–98.

    Article  CAS  Google Scholar 

  41. Yajima S, Sugawara K, Iwai M, et al. Efficacy and safety of a third-generation oncolytic herpes virus G47Δ in models of human esophageal carcinoma. Mol Ther Oncol. 2021;23:402–11.

    Article  CAS  Google Scholar 

  42. Inoue K, Ito H, Iwai M, et al. Neoadjuvant use of oncolytic herpes virus G47delta prevents stage advancement of tongue cancer. Cancer Sci. 2022;113:1422.

    Google Scholar 

  43. Cheema TA, Fecci PE, Ning J, et al. Immunovirotherapy for the treatment of glioblastoma. OncoImmunology. 2014;3(1): e27218.

    Article  Google Scholar 

  44. Esaki S, Rabkin SD, Martuza RL, et al. Transient fasting enhances replication of oncolytic herpes simplex virus in glioblastoma. Am J Cancer Res. 2016;6(2):300–11.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Saha D, Rabkin SD, Martuza RL. Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma. J Immunother Cancer. 2020;8(Suppl 1): e000345.

    Article  Google Scholar 

  46. Todo T, Ino Y, Ohtsu H, et al. A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastoma. Nat Commun. 2022;13(1):4119.

    Article  CAS  Google Scholar 

  47. Todo T. Results of phase ii clinical trial of oncolytic herpes virus G47delta in patients with glioblastoma [abstract no. ATIM-14]. Neuro Oncol. 2019;21(Suppl 6):vi4.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand

    James E. Frampton

Authors
  1. James E. Frampton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James E. Frampton.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and conflict of interest

During the peer review process the manufacturer of teserpaturev/G47Δ was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. James E. Frampton is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability

Not applicable.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PPTX 73 KB)

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Frampton, J.E. Teserpaturev/G47Δ: First Approval. BioDrugs 36, 667–672 (2022). https://doi.org/10.1007/s40259-022-00553-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40259-022-00553-7

Search

Navigation